Business Context and Reporting Period
This Form 6-K filing by Genenta Science S.P.A. covers the month of October 2025. The report details the outcomes of the Ordinary and Extraordinary Shareholders' Meeting held on October 29, 2025, in a virtual format. The Company is a foreign private issuer based in Milan, Italy.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance changes and shareholder resolutions rather than financial performance data.
Material Changes
- Board Expansion: The number of Board of Directors members increased from three to five.
- New Appointments: Miguel Maria Mutti and Giacomoantonio Paracchi were appointed as new directors effective October 29, 2025. Their terms last until the Shareholders' Meeting approving the financial statements as of December 31, 2025.
- Compensation Adjustment: The aggregate annual gross compensation for the two new directors is set at €60,000. The total remuneration for the entire Board has been redetermined to €165,000.
- By-laws Amendment: Article 4 of the by-laws was amended to extend the Company's corporate purpose to include sectors covered by Italian Law Decree 21/2012 (Golden Power legislation).
- Capital Structure Update: The filing references a recent capital increase involving the issuance of 4,285,715 new shares pursuant to a prospectus supplement filed on October 28, 2025, though the updated share capital amount is not yet reflected in the attached by-laws.
Outlook, Risks, and Contingencies
Contingency on By-laws Amendment: The effectiveness of the by-laws amendment regarding the Golden Power legislation is expressly conditioned on the non-exercise of the withdrawal right (diritto di recesso) by shareholders who did not vote in favor. If even a single shareholder validly exercises this right, the amendment will not take effect.
Withdrawal Procedure: Shareholders must exercise the right of withdrawal by sending a registered letter to the Company within fifteen days of the resolution's registration in the Companies' Register (approximately by November 15, 2025). The letter must include personal details, communication address, and the number of shares involved.
Management Commentary: The new directors bring significant experience: Mr. Mutti offers over 25 years in pharmaceuticals and investment banking, while Mr. Paracchi provides extensive legal and corporate affairs expertise. Mr. Paracchi is the brother of the CEO, Pierluigi Paracchi.
Investor Verification Checklist
- Verify whether any shareholders exercised the right of withdrawal by the November 15, 2025 deadline, as this determines the validity of the Golden Power by-laws amendment.
- Confirm the final updated share capital amount following the issuance of 4,285,715 new shares, as the current by-laws exhibit does not yet reflect this figure.
- Review the full text of the Amended By-laws (Exhibit 3.1) for specific details on the expanded corporate purpose.
- Monitor future filings for the financial statements as of December 31, 2025, which will conclude the terms of the newly appointed directors.